GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SomaLogic Inc (NAS:SLGC) » Definitions » EBIT

SomaLogic (SomaLogic) EBIT : $-86.65 Mil (TTM As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SomaLogic EBIT?

SomaLogic's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $-23.93 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $-86.65 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. SomaLogic's annualized ROC % for the quarter that ended in Sep. 2023 was -100.35%. SomaLogic's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -319.39%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. SomaLogic's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 158.05%.


SomaLogic EBIT Historical Data

The historical data trend for SomaLogic's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomaLogic EBIT Chart

SomaLogic Annual Data
Trend Dec20 Dec21 Dec22
EBIT
-34.68 -86.19 -109.87

SomaLogic Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.89 8.57 -40.19 -31.10 -23.93

Competitive Comparison of SomaLogic's EBIT

For the Health Information Services subindustry, SomaLogic's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SomaLogic's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, SomaLogic's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SomaLogic's EV-to-EBIT falls into.



SomaLogic EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-86.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SomaLogic  (NAS:SLGC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

SomaLogic's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

ROC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=-95.7 * ( 1 - -2.2% )/( (96.723 + 98.212)/ 2 )
=-97.8054/97.4675
=-100.35 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

SomaLogic's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-95.7/( ( (18.668 + max(10.572, 0)) + (18.172 + max(12.514, 0)) )/ 2 )
=-95.7/( ( 29.24 + 30.686 )/ 2 )
=-95.7/29.963
=-319.39 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(21.75 + 15.123 + 5.2) - (14.833 + 5.083 + 11.585)
=10.572

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(20.73 + 13.884 + 5.681) - (13.026 + 3.074 + 11.681)
=12.514

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

SomaLogic's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2023 )
=-86.646/-54.821
=158.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SomaLogic EBIT Related Terms

Thank you for viewing the detailed overview of SomaLogic's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


SomaLogic (SomaLogic) Business Description

Traded in Other Exchanges
N/A
Address
2945 Wilderness Place, Boulder, CO, USA, 80301
SomaLogic is a commercial-stage proteomics company. It operates as a protein biomarker discovery and clinical diagnostics company that develops slow off-rate modified aptamers, which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The Somamers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.
Executives
Alison Marie Roelke officer: Chief People Officer 900 INNOVATORS WAY, SIMI VALLEY CA 93065
Adam Taich officer: Interim CEO C/O SOMALOGIC, INC., 2945 WILDERNESS PLACE, BOULDER CO 80301
Ruben Gutierrez officer: General Counsel 6435 AVENIDA WILFREDO, LA JOLLA CA 92037
Kathy L Hibbs director C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
Jason Ryan director C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas D. Carey director 8 PAIGE STREET, HINGHAM MA 02043
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Tycho Peterson director C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Shaun M. Blakeman officer: Chief Financial Officer C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Anne H. Margulies director C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Richard A Post director 998 LACOSTA LANE, LANE TREE CO 80124
Charles M. Lillis director 13 CASTLE PINES DRIVE N, CASTLE ROCK CO 80108
Stephen Quake director C/O FLUIDIGM CORPORATION, 7000 SHORELINE COURT, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Robert Barchi director